CNMD vs IRMD

CNMD exhibits a stark divergence between its strong balance sheet health (Piotroski F-Score: 7/9) and its deteriorating operational performance. While the company maintains a stable financial foundation and a low Price-to-Sales ratio, it is plagued by a severe earnings collapse (-50% YoY) and a consistent track record of missing analyst estimates (0/4 beats in the last year). With the current price ($38.34) trading above the Graham Number ($33.66) and significantly above the growth-based intrinsic value ($10.57), the stock lacks a valuation catalyst despite a low forward P/E.

IRMD presents a dichotomy between exceptional operational performance and extreme valuation premiums. While the Piotroski F-Score of 4/9 indicates stable financial health and the company boasts an impressive 76.75% gross margin and a consistent 25-quarter earnings beat record, the stock is trading significantly above its Graham Number ($17.07) and Intrinsic Value ($51.62). The strong fundamental growth is currently offset by bearish insider activity from the CEO and a completely bearish technical trend (0/100).